Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2007

Abraxis Obtains North American and EU Rights to Biocon’s G-CSF Biosimilar

  • Abraxis BioScience licensed the right to develop a biosimilar version of G-CSF (granulocyte-colony stimulating factor) in North America and the EU from Biocon.

    Therapeutic G-CSF is primarily used for the treatment of neutropenia. Biocon received regulatory approval from the Indian DCGI for the treatment of neutropenia in cancer patients.

    Under the terms of the agreement, Biocon will receive an upfront licensing fee and following approval in the licensed territories, royalties from Abraxis BioScience.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »